QuSecure Collaborates with Red Hat to Deliver Enhanced Post-Quantum Cryptography Modernization
QuSecure Provides a More Easily Deployed Crypto-Agile Cybersecurity Solution Using Red Hat Open-Source Technologies SAN…
Year: 2023
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer…
Viz.ai Wins 2023 Gold Edison Award™ for Innovation
Honored for excellence in innovation in AI Assisted Medicine SAN FRANCISCO–(BUSINESS WIRE)–#ai–Viz.ai, the leader in…
AMTD IDEA Group Achieved a 22.74% Increase in Core Revenue and Successfully Announced the First Set of Consolidated Annual Financials Including AMTD Digital Inc. and L’Officiel Inc. SAS
NEW YORK & HONG KONG & SINGAPORE–(BUSINESS WIRE)–AMTD IDEA Group (“AMTD IDEA” or the “Company”,…
New Partnership for Sustainable Building Experts Signals Commitment to Low-Carbon Innovation
Collaboration Between cove.tool and Zauben to Drive Integration of Nature-Based Technologies into Built Environment ATLANTA–(BUSINESS…
Results from New Studies Support Role of Digital Tools in Streaming Dementia Detection; Findings to be Revealed at American Academy of Neurology’s Annual Meeting
Linus Health to present new findings on accuracy and reliability of tech-enabled cognitive assessments BOSTON–(BUSINESS…
Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023
Data accepted as AAN Late-Breaking Abstract THE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) —…
Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference
WATERTOWN, Mass., April 21, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical…
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
The application is for a novel psychedelic-based combination, of Clearmind’s MEAI and SciSparc’s Cannamide™ Tel…
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
The application refers to a novel psychedelic-based combination of Clearmind’s MEAI and SciSparc’s Cannamide™ TEL AVIV, Israel,…
LianBio Promotes Pascal Qian to Chief Commercial Officer
SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…
Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 21, 2023 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA),…
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical…
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
Seasoned operating executive with successful track record at late-stage biopharmaceutical companies FARMINGTON HILLS, Mich., April…
LianBio Announces China National Medical Products Administration (NMPA) Acceptance with Priority Review of New Drug Application for Mavacamten for the Treatment of Patients with Obstructive Hypertrophic Cardiomyopathy
SHANGHAI, China and PRINCETON, N.J., April 21, 2023 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a…
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
Applications are under review in Canada, Australia, the United Kingdom, and Switzerland Approval decisions expected…
Cronos Group Releases Cannabinoid Life Cycle Study Highlighting its Sustainable Fermentation Practices
TORONTO, April 21, 2023 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”…
Freeline Announces Proposed ADS Ratio Change
LONDON, April 21, 2023 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced…
XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease
CALGARY, Alberta, April 21, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”)…
Kovo HealthTech Closes CDN$4.4M Private Placement and Secures Strategic Financing up to USD$7M
Vancouver, British Columbia–(Newsfile Corp. – April 21, 2023) – Kovo HealthTech Corporation (TSXV: KOVO) (the “Company”…